Safety and durability of the immune response after vaccination with the heterologous schedule of anti-COVID-19 vaccines SOBERANA®02 and SOBERANA® Plus in children 3–18 years old

Safety and durability of the immune response after vaccination with the heterologous schedule of anti-COVID-19 vaccines SOBERANA®02 and SOBERANA® Plus in children 3–18 years old

Background: The heterologous three-dose schedule of the protein subunit anti-COVID-19 SOBERANA®02 and SOBERANA® Plus vaccines has proved its safety, immunogenicity and efficacy in pediatric population, but durability of immunogenicity is not yet dilucidated. This study reports the safety and durabil...

Full description

Saved in:
Bibliographic Details
Main Authors: Dagmar García-Rivera, Rinaldo Puga-Gómez, Sonsire Fernández-Castillo, Beatriz Paredes-Moreno, Yariset Ricardo-Delgado, Meiby Rodríguez-González, Carmen Valenzuela Silva, Rocmira Pérez-Nicado, Laura Rodríguez-Noda, Darielys Santana-Mederos, Yanet Climent-Ruiz, Enrique Noa-Romero, Otto Cruz-Sui, Belinda Sánchez-Ramírez, Tays Hernández-García, Ariel Palenzuela-Diaz, Marisel Martínez-Perez, Arilia García-López, Yury Valdés-Balbín, Vicente G. Vérez-Bencomo
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Vaccine: X
Subjects:
COVID-19 vaccine
RBD
Cellular response
Pediatric vaccine
Conjugate vaccine
Subunit vaccine
Online Access:http://www.sciencedirect.com/science/article/pii/S2590136224001682
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2590136224001682

Similar Items